跳转至内容
Merck

PZ0327

Sigma-Aldrich

PF06650833

≥98% (HPLC)

别名:

1-[[(2S,3S,4S)-3-乙基-4-氟-5-氧代-2-吡咯烷基]甲氧基] -7-甲氧基-6-异喹啉羧酰胺, PF-06650833

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C18H20FN3O4
分子量:
361.37
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 20 mg/mL, clear

儲存溫度

room temp

SMILES 字串

NC(C1=C(OC)C=C2C(C=CN=C2OC[C@@H]3[C@H](CC)[C@H](F)C(N3)=O)=C1)=O

InChI

1S/C18H20FN3O4/c1-3-10-13(22-17(24)15(10)19)8-26-18-11-7-14(25-2)12(16(20)23)6-9(11)4-5-21-18/h4-7,10,13,15H,3,8H2,1-2H3,(H2,20,23)(H,22,24)/t10-,13+,15-/m0/s1

InChI 密鑰

JKDGKIBAOAFRPJ-ZBINZKHDSA-N

生化/生理作用

PF06650833已被研究用于治疗Waldenstrom巨球蛋白血症,其表现为可产生IgM(免疫球蛋白M)的淋巴浆细胞的过量产生。
PF06650833是白介素-1受体相关激酶4(IRAK4)的一种抑制剂。IRAK4激酶在先天免疫中具有重要作用,可参与到来自Toll样受体和einterleukin-1受体家族成员的信号转导启动。IRAK4激酶是治疗与炎症失调相关的各种疾病,如类风湿关节炎、骨关节炎、炎症性肠病和系统性红斑狼疮的一种重要靶标。PF06650833已被研究用于治疗狼疮。

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sadiq Umar et al.
Cellular & molecular immunology (2020-05-18)
Flares of joint inflammation and resistance to currently available biologic therapeutics in rheumatoid arthritis (RA) patients could reflect activation of innate immune mechanisms. Herein, we show that a TLR7 GU-rich endogenous ligand, miR-Let7b, potentiates synovitis by amplifying RA monocyte and
Rafael Deliz-Aguirre et al.
The Journal of cell biology, 220(7) (2021-05-07)
A recurring feature of innate immune receptor signaling is the self-assembly of signaling proteins into oligomeric complexes. The Myddosome is an oligomeric complex that is required to transmit inflammatory signals from TLR/IL1Rs and consists of MyD88 and IRAK family kinases.
Kinase inhibitors in clinical practice: An expanding world.
Pandey R and Reuben K
The Journal of Allergy and Clinical Immunology, 141(2), 522-524 (2018)
Future therapeutic options for patients with Waldenstrom macroglobulinemia.
Castillo J J, et al.
Best Practice & Research. Clinical Haematology, 29(2), 206-215 (2016)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门